12 May 2022 | News
The drug combines two proven blockbuster monoclonal antibodies in a single vial for subcutaneous administration
Roche Pharma has announced the India launch of PHESGO – the first ever fixed dose formulation in oncology to combine two monoclonal antibodies - Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC injection.
PHESGO can be administered as a single injection just under the skin in the thigh and it takes a few minutes compared to hours with IV formulations for each round of treatment, thus reducing chair time for patients by 90 per cent.
PHESGO can help breast cancer patients continue receiving their treatment due to significantly shorter administration times and the convenience of subcutaneous administration, potentially moving the treatment from oncology wards to daycare and OPD settings.